Psoriasis is a common disease, which has a considerable impact on patients and the health
care system. Treatment approaches to the disease may be various because some issues …

Tuberculosis is an infectious disease with a major global impact, ranked in the top 10
mortality causes worldwide. In an immunocompetent individual, the host defence …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Methotrexate (MTX) is one of the first-line treatments for moderate to severe psoriasis, while
the side effects caused by injection and oral administration of MTX greatly restrict its clinical …

Background Immune checkpoint inhibitor (ICI)–mediated psoriasis poses significant
diagnostic and therapeutic challenges. Objective To report data on ICI-mediated psoriasis …

Tildrakizumab, an IL-23 inhibitor, is effective and safe for the improvement of moderate-to-
severe chronic plaque psoriasis. However, little evidence is available on the use of this …

Psoriasis is a common immune-mediated chronic skin disease. Disease severity is
influenced by several factors including the extent and localization of skin lesions, severity of …

Little information is available from real-life studies evaluating the efficacy of guselkumab in
moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database …

Introduction Treat-to-target strategies are used in several chronic diseases to improve
outcomes. Treatment goals have also been suggested for psoriasis, but there is currently no …

SARS‐CoV‐2 become pandemics and there is still a dearth of data about its the potentially
among dermatological patients under biologics. We aimed to assess health literacy, disease …